These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 31545110)
21. Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial. Vieira CS; de Nadai MN; de Melo Pereira do Carmo LS; Braga GC; Infante BF; Stifani BM; Ferriani RA; Quintana SM Contraception; 2019 Oct; 100(4):258-263. PubMed ID: 31145885 [TBL] [Abstract][Full Text] [Related]
22. Gene expression associated with unfavorable vaginal bleeding in women using the etonogestrel subdermal contraceptive implant: a prospective study. Torelli FR; Rodrigues-Peres RM; Monteiro I; Lopes-Cendes I; Bahamondes L; Juliato CRT Sci Rep; 2024 May; 14(1):11062. PubMed ID: 38745005 [TBL] [Abstract][Full Text] [Related]
23. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant. Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644 [TBL] [Abstract][Full Text] [Related]
24. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant. Deokar AM; Jackson W; Omar HA Int J Adolesc Med Health; 2011; 23(1):75-7. PubMed ID: 21721368 [TBL] [Abstract][Full Text] [Related]
25. Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users: A Randomized Controlled Trial. Zigler RE; Madden T; Ashby C; Wan L; McNicholas C Obstet Gynecol; 2018 Oct; 132(4):888-894. PubMed ID: 30130351 [TBL] [Abstract][Full Text] [Related]
26. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion. Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190 [TBL] [Abstract][Full Text] [Related]
27. Use of etonogestrel subcutaneous implant in Sardinia, Italy: women's compliance and satisfaction. Capobianco G; Sanna E; Gulotta A; Virdis G; Dessole F; Maida I; Madonia M; Cudoni F; Petrillo M Eur J Contracept Reprod Health Care; 2024 Aug; 29(4):171-176. PubMed ID: 38785129 [TBL] [Abstract][Full Text] [Related]
28. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Guazzelli CA; de Queiroz FT; Barbieri M; Torloni MR; de Araujo FF Contraception; 2010 Sep; 82(3):256-9. PubMed ID: 20705154 [TBL] [Abstract][Full Text] [Related]
29. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting. Howard DL; Ford A; Ceballos S; Volker KW J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797 [TBL] [Abstract][Full Text] [Related]
30. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Flores JB; Balderas ML; Bonilla MC; Vázquez-Estrada L Int J Gynaecol Obstet; 2005 Sep; 90(3):228-33. PubMed ID: 16043175 [TBL] [Abstract][Full Text] [Related]
31. Bleeding profile in users of an etonogestrel sub-dermal implant: effects of anthropometric variables. An observational uncontrolled preliminary study in Italian population. Di Carlo C; Guida M; De Rosa N; Sansone A; Gargano V; Cagnacci A; Nappi C Gynecol Endocrinol; 2015 Jun; 31(6):491-4. PubMed ID: 26213863 [TBL] [Abstract][Full Text] [Related]
32. Continuation rates of the subdermal contraceptive Implanon(®) and associated influencing factors. Teunissen AM; Grimm B; Roumen FJ Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):15-21. PubMed ID: 24329119 [TBL] [Abstract][Full Text] [Related]
33. Etonogestrel implant use in women primarily choosing a combined oral contraceptive pill: A proof-of-concept trial. Chen MJ; Hsia JK; Creinin MD Contraception; 2018 Jun; 97(6):533-537. PubMed ID: 29496473 [TBL] [Abstract][Full Text] [Related]
34. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. McNicholas C; Swor E; Wan L; Peipert JF Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241 [TBL] [Abstract][Full Text] [Related]
35. Indications for removal of etonogestrel implant within two years of use in Jos, Nigeria. Mutihir JT; Nyango DD East Afr Med J; 2010 Nov; 87(11):461-4. PubMed ID: 23457809 [TBL] [Abstract][Full Text] [Related]
36. Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial. Edelman AB; Kaneshiro B; Simmons KB; Hauschildt JL; Bond K; Boniface ER; Jensen JT Obstet Gynecol; 2020 Aug; 136(2):323-332. PubMed ID: 32649493 [TBL] [Abstract][Full Text] [Related]
37. Postpartum contraception: initiation and effectiveness in a large universal healthcare system. Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962 [TBL] [Abstract][Full Text] [Related]
38. One-year assessment of women receiving sub-dermal contraceptive implant at Siriraj Family Planning Clinic. Thamkhantho M; Jivasak-Apimas S; Angsuwathana S; Chiravacharadej G; Intawong J J Med Assoc Thai; 2008 Jun; 91(6):775-80. PubMed ID: 18697372 [TBL] [Abstract][Full Text] [Related]
39. Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial. Lombardi Fäh V; Catarino R; Castillo S; Badda M; Gezer-Dickschat S; Thieringer F; Tschudin S; Viviano M; Yaron M BMC Res Notes; 2023 Mar; 16(1):35. PubMed ID: 36915205 [TBL] [Abstract][Full Text] [Related]
40. Association of body mass index with removal of etonogestrel subdermal implant. Casey PM; Long ME; Marnach ML; Fleming-Harvey J; Drozdowicz LB; Weaver AL Contraception; 2013 Mar; 87(3):370-4. PubMed ID: 22959901 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]